Eli Lilly says its new treatment against Alzheimer's has shown to slow the disease's progression. Clinical trial included 1,200 participants between the ages of 60 and 85 who had not yet reached an advanced stage of the disease.
Treatment can cause serious side effects, such as edema or cerebral hemorrhage. Three participants in the clinical trial died, according to the company. The company plans to file an application for authorization with the U.S. Food and Drug Administration as early as this quarter, and worldwide "as soon as possible"